Alimera Sciences (NASDAQ:ALIM) Downgraded by StockNews.com to Hold

Alimera Sciences (NASDAQ:ALIM) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Friday.

Separately, Maxim Group began coverage on shares of Alimera Sciences in a report on Monday, March 25th. They set a “buy” rating and a $10.00 price target for the company.

Alimera Sciences Trading Down 8.6 %

Shares of NASDAQ:ALIM opened at $3.52 on Friday. The stock has a market capitalization of $184.27 million, a PE ratio of -1.63 and a beta of 1.18. Alimera Sciences has a 1 year low of $1.56 and a 1 year high of $4.38. The firm has a fifty day moving average price of $3.76 and a 200 day moving average price of $3.60. The company has a current ratio of 2.39, a quick ratio of 2.31 and a debt-to-equity ratio of 1.40.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). The business had revenue of $26.31 million during the quarter, compared to the consensus estimate of $25.10 million. Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. During the same quarter in the prior year, the company posted ($0.54) earnings per share. Analysts expect that Alimera Sciences will post 0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Alimera Sciences

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC bought a new stake in shares of Alimera Sciences in the fourth quarter valued at about $32,000. Osaic Holdings Inc. bought a new stake in shares of Alimera Sciences in the second quarter valued at about $34,000. Tower Research Capital LLC TRC lifted its stake in shares of Alimera Sciences by 291.8% in the third quarter. Tower Research Capital LLC TRC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 8,937 shares during the period. Northern Trust Corp acquired a new position in Alimera Sciences in the fourth quarter worth about $61,000. Finally, Citadel Advisors LLC acquired a new position in Alimera Sciences in the fourth quarter worth about $86,000. 99.83% of the stock is currently owned by institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).